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Objective: Gene expression analysis is widely used in most of studies of transcriptomic. If the cryopreserved samples' storage time may influence the expression levels of genes is unknown. We aim to test the status of gene expression of different sample storage time during the cryopreserved processing by RNA sequencing. Methods: We selected one tissue sample of bladder cancer to be cryopreserved. Firstly the sample was prepared to cell suspension divided into five centrifuge tube. One of 5 was undergone RNA sequencing processing immediately. The rest of them were storage in −80 ℃ by temperature gradient cooling method, and performed RNA sequencing after 18 h, 66 h, 10 d, 30 d of storage. Then, we calculated the RPKM and FPKM of all mapped genes and those of 12 housekeeping genes. Results: Less than 30 d tissue storage had little effect on the total gene expression but induced changes in the transcript levels of stress-responsive genes as COX family after 18 h. Among the house keeping genes tested, the chosen 12 genes is stable. Conclusions: This study shows that the bladder cancer sample storage in −80 ℃ can be used in related research refer to RNA sequencing. The most genes expression is stable except several stress-responsive genes. Objective: Nucleolar and spindle-associated protein 1 (NUSAP1) is a microtubule-binding protein that plays an essential role in mitosis and cancer. Previous studies have demonstrated that NUSAP1 expression was relatively elevated in several malignancies. However, the biological roles of NUSAP1 in renal cell carcinoma (RCC) remain unknown. Methods: In the present study, we firstly performed reverse transcription polymerase chain reaction (RT-PCR) and western blot (WB) assay to reveal that the expression of NUSAP1 was relatively elevated in clear cell RCC (ccRCC) tissue specimens and RCC cell lines. Results: Immunohistochemical analysis showed that upregulation of NUSAP1 was significantly correlated with Fuhrman grade (P<0.001), tumor size (P=0.016), clinical stage (P<0.001) and distant metastasis (P=0.023). Additionally, high expression of NUSAP1 was closely associated with a shorter overall survival time of ccRCC patients (P=0.006). Further, we investigated the biological behaviors of RCC cells in vitro, and we identified that NUSAP1 depletion inhibited RCC cell migration, Objective: The management of stage 1 and grade 3 (T1G3) bladder cancer continues to be controversial. Although the transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy is a conservative strategy for treatment of T1G3 bladder cancer, a relatively high risk of tumor recurrence and progression remains regarding the therapy. This study aimed to compare the efficacy of intravenous chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone for T1G3 bladder cancer after TURBT surgery.
Methods:
We retrospectively reviewed the cases of 457 patients who were newly diagnosed with T1G3 bladder urothelial carcinoma between January 2009 and March 2014. After TURBT, 281 patients received intravesical chemotherapy alone, whereas 176 patients underwent intravesical chemotherapy in combination with intravenous chemotherapy. Tumor recurrence and progression were monitored periodically by urine cytology and cystoscopy in follow-up. Recurrence-free survival and progressionfree survival of the two chemotherapy strategies following TURBT were analyzed. Univariable and multivariable Cox hazards analyses were performed to predict the prognostic factors for tumor recurrence and progression. Results: The tumor recurrence rate was 36.7% for patients who received intravesical chemotherapy alone after TURBT, compared with 19.9% for patients who received intravenous chemotherapy combined with intravesical chemotherapy after TURBT (P<0.001). The progression rate was 10.6% for patients who underwent intravesical chemotherapy alone and 2.3% for patients who underwent the combined chemotherapies (P=0.003). Kaplan-Meier curves showed significant differences in recurrence-free survival and progression-free survival between the two treatment strategies, with a log-rank P value of <0.001 and 0.003, respectively. Multivariable analyses revealed that intravenous chemotherapy was the independent prognostic factor for tumor recurrence and progression in the cohort. Conclusions: Intravenous chemotherapy combined with intravesical chemotherapy offers a better oncologic outcome than the intravesical chemotherapy alone for patients with T1G3 bladder urothelial carcinoma after TURBT, and it may be considered as a new therapy strategy for T1G3 bladder cancer. 
